RESUMO
It is unclear whether priming of naïve T cells to drugs is detectable in healthy human donors expressing different human leukocyte antigen (HLA) alleles. Thus, we examined T cell priming with drugs associated with HLA risk alleles and control compounds in 14 HLA-typed donors. Nitroso sulfamethoxazole and piperacillin activated T cells from all donors, whereas responses to carbamazepine and oxypurinol were only seen in donors expressing HLA-B*15:02 and HLA-B*58:01, respectively. Weak flucloxacillin-specific T cell responses were detected in donors expressing HLA-B*57:01 and HLA-B*58:01. These data show that the priming of T cells with certain drugs is skewed toward donors expressing specific HLA alleles.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/imunologia , Antígenos HLA/imunologia , Ativação Linfocitária/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Anti-Infecciosos/efeitos adversos , Anti-Infecciosos/imunologia , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/imunologia , Carbamazepina/efeitos adversos , Carbamazepina/imunologia , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/imunologia , Antígenos HLA-B/imunologia , Humanos , Compostos Nitrosos/efeitos adversos , Compostos Nitrosos/imunologia , Oxipurinol/efeitos adversos , Oxipurinol/imunologia , Piperacilina/efeitos adversos , Piperacilina/imunologia , Sulfametoxazol/efeitos adversos , Sulfametoxazol/imunologia , Linfócitos T/imunologiaRESUMO
Safe and efficacious vaccines are arguably the most successful medical interventions of all time. Yet the ongoing discovery of new pathogens, along with emergence of antibiotic-resistant pathogens and a burgeoning population at risk of such infections, imposes unprecedented public health challenges. To meet these challenges, innovative strategies to discover and develop new or improved anti-infective vaccines are necessary. These approaches must intersect the most meaningful insights into protective immunity and advanced technologies with capabilities to deliver immunogens for optimal immune protection. This goal is considered through several recent advances in host-pathogen relationships, conceptual strides in vaccinology, and emerging technologies. Given a clear and growing risk of pandemic disease should the threat of infection go unmet, developing vaccines that optimize protective immunity against high-priority and antibiotic-resistant pathogens represents an urgent and unifying imperative.
Assuntos
Anti-Infecciosos/administração & dosagem , Invenções/tendências , Vacinas/administração & dosagem , Animais , Anti-Infecciosos/imunologia , Anti-Infecciosos/metabolismo , Doenças Transmissíveis/tratamento farmacológico , Doenças Transmissíveis/imunologia , Doenças Transmissíveis/metabolismo , Humanos , Imunidade Inata/efeitos dos fármacos , Imunidade Inata/fisiologia , Resultado do Tratamento , Vacinas/imunologia , Vacinas/metabolismoRESUMO
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world.
Assuntos
Anti-Infecciosos/síntese química , Anti-Infecciosos/economia , Anticorpos Monoclonais/biossíntese , Anticorpos Anti-HIV/biossíntese , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Administração Intravaginal , Animais , Anti-Infecciosos/imunologia , Anticorpos Monoclonais/isolamento & purificação , Cromatografia de Afinidade , Análise Custo-Benefício , Cricetinae , Cricetulus , Vias de Administração de Medicamentos , Eletroforese em Gel de Poliacrilamida , Glicopeptídeos/química , Anticorpos Anti-HIV/isolamento & purificação , Antígenos HIV/imunologia , Infecções por HIV/imunologia , Humanos , Espectrometria de Massas , Peso Molecular , Testes de Neutralização , Plantas Geneticamente Modificadas , Polissacarídeos/análise , Sementes/metabolismo , Proteína Estafilocócica A/metabolismo , Zea mays/genéticaRESUMO
Theory predicts that natural selection will erode additive genetic variation in fitness-related traits. However, numerous studies have found considerable heritable variation in traits related to immune function, which should be closely linked to fitness. This could be due to trade-offs maintaining variation in these traits. We used the Egyptian cotton leafworm, Spodoptera littoralis, as a model system to examine the quantitative genetics of insect immune function. We estimated the heritabilities of several different measures of innate immunity and the genetic correlations between these immune traits and a number of life history traits. Our results provide the first evidence for a potential genetic trade-off within the insect immune system, with antibacterial activity (lysozyme-like) exhibiting a significant negative genetic correlation with haemocyte density, which itself is positively genetically correlated with both haemolymph phenoloxidase activity and cuticular melanization. We speculate on a potential trade-off between defence against parasites and predators, mediated by larval colour, and its role in maintaining genetic variation in traits under natural selection.
Assuntos
Variação Genética , Seleção Genética , Spodoptera/imunologia , Análise de Variância , Animais , Anti-Infecciosos/imunologia , Contagem de Células Sanguíneas , Peso Corporal , Larva/crescimento & desenvolvimento , Larva/imunologia , Funções Verossimilhança , Longevidade , Melaninas/metabolismo , Monofenol Mono-Oxigenase/sangue , Muramidase/imunologia , Densidade Demográfica , Característica Quantitativa Herdável , Spodoptera/genética , Spodoptera/crescimento & desenvolvimentoRESUMO
BACKGROUND: Human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) have experienced a dramatic decrease in Pneumocystis carinii pneumonia (PCP), necessitating reassessment of clinical guidelines for prophylaxis. METHODS: A simulation model of HIV infection was used to estimate the lifetime costs and quality-adjusted life expectancy (QALE) for alternative CD4 cell count criteria for stopping primary PCP prophylaxis in patients with CD4 cell count increases receiving HAART and alternative agents for second-line PCP prophylaxis in those intolerant of trimethoprim-sulfamethoxazole (TMP/SMX). The target population was a cohort of HIV-infected patients in the United States with initial CD4 cell counts of 350/microL who began PCP prophylaxis after their first measured CD4 lymphocyte count less than 200/microL. Data were from randomized controlled trials and other published literature. RESULTS: For patients with CD4 cell count increases during HAART, waiting to stop prophylaxis until the first observed CD4 cell count was greater than 300/microL prevented 9 additional cases per 1000 patients and cost $9400 per quality-adjusted life year (QALY) gained compared with stopping prophylaxis at 200/microL. For patients intolerant of TMP/SMX, using dapsone increased QALE by 2.7 months and cost $4500 per QALY compared with no prophylaxis. Using atovaquone rather than dapsone provided only 3 days of additional QALE and cost more than $1.5 million per QALY. CONCLUSIONS: Delaying discontinuation of PCP prophylaxis until the first observed CD4 cell count greater than 300/microL is cost-effective and provides an explicit "PCP prophylaxis stopping criterion." In TMP/SMX-intolerant patients, dapsone is more cost-effective than atovaquone.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Anti-Infecciosos/uso terapêutico , Antiprotozoários/uso terapêutico , Dapsona/uso terapêutico , Modelos Teóricos , Naftoquinonas/uso terapêutico , Pentamidina/uso terapêutico , Pneumonia por Pneumocystis/prevenção & controle , Guias de Prática Clínica como Assunto/normas , Infecções Oportunistas Relacionadas com a AIDS/economia , Infecções Oportunistas Relacionadas com a AIDS/imunologia , Anti-Infecciosos/economia , Anti-Infecciosos/imunologia , Antiprotozoários/economia , Antiprotozoários/imunologia , Atovaquona , Contagem de Linfócito CD4/economia , Análise Custo-Benefício/economia , Dapsona/economia , Dapsona/imunologia , Custos de Medicamentos , Humanos , Expectativa de Vida , Naftoquinonas/economia , Naftoquinonas/imunologia , Pentamidina/economia , Pentamidina/imunologia , Pneumonia por Pneumocystis/economia , Pneumonia por Pneumocystis/imunologia , Anos de Vida Ajustados por Qualidade de VidaRESUMO
A 19-year-old man was treated with trimethoprim-sulphamethoxazole intermittently over 4 weeks. He developed a rash and fever. Despite treatment with low-dose methylprednisolone, his condition worsened. He developed a confluent erythematous macular eruption, elevated liver enzymes, lymphadenopathy, polyserositis and eosinophilia. A tentative diagnosis of sulphonamide hypersensitivity syndrome reaction (SHSR) was made and a serum sample (acute) was obtained to screen for antibodies associated with SHSR. Intravenous methylprednisolone sodium succinate (250 mg every 6 h for 48 h) was administered. The patient's condition improved, and he was discharged with oral prednisone. A convalescent serum sample was obtained 14 weeks later. By Western blotting and enzyme-linked immunosorbent assay (ELISA), antisulphamethoxazole IgG antibodies were detected in the acute serum sample, supporting the clinical diagnosis of SHSR. Contrary to expectations, antibodies were not detected in the convalescent serum sample by immunoblotting. Antisulphamethoxazole antibodies were detected by ELISA in the convalescent serum, but the titre was decreased approximately 45-fold. One possible explanation for the decrease in antibody concentration in the convalescent sample was the administration of high-dose glucocorticoids to the patient following collection of the acute serum sample.